Cost variation analysis of different brands of oral anti-epileptic drugs available in India

Nagavishnu Kandra, Rajesh B.


Background: Epilepsy is a group of neurological disorders, characterized by seizures, loss of consciousness, muscular contraction. Prevalence of epilepsy in India is about 1%. High medical care cost should be cause of concern for policy makers and service providers. Hence, a study was planned to analyse cost ratio and percentage cost variations of oral antiepileptic drugs available in India.

Methods: An analytical study with maximum and minimum price of 10 tablets/capsules and syrup of one bottle of available strength of each drug was noted in Indian Rupee, using “Current Index of Medical Specialties” July to October 2020; “Drug Today” July To October 2020 volume-1 and “Indian Drug Review” 2020 volume-26 issue 6. Percentage cost variation and cost ratio for individual drugs was compared.

Results: Significant cost variations were found in different brands of same drug. Among established oral antiepileptic drugs, Divalproex sodium 250 mg has highest cost ratio 16.071 and 1507.14% price variation and Clonazepam 0.25 mg with cost ratio 16.005 and 1500.55% price variation. Diazepam 2 mg has lowest cost ratio 1.024 and 2.43% price variation. Among newer oral antiepileptic drugs, Levetiracetam 500 mg has highest cost ratio 66.389 and 6538.93% price variation; least is Oxcarbazepine 450 mg with cost ratio 1.317 and 31.75% price variation.

Conclusions: Epilepsy has long course of treatment. Increased adherence to treatment is achieved by switching to cost-effective therapy and by making Pharmacoeconomics an integral part of Undergraduate and Postgraduate Curriculum.


Anti-epileptic drugs, Cost ratio, Percentage cost variation

Full Text:



Chang BS, Lowenstein DH. Epilepsy. N Engl J Med. 2003;349(13):1257-66.

Arya P, Kumar R, Chandra A, Mohan L. Study of price variations of anti-epileptic drugs available in different brands in Indian pharmaceutical market. Int J Res Med Sci. 2018;6:4102-5.

WHO. Neurological disorders: Public health challenges. Geneva: World Health Organization. 2006. gy/neurological_disorders_report_web.pdf. Accessed on 03 May, 2021.

Sridharan R, Murthy BN. Prevalence and pattern of epilepsy in India. Epilepsia. 1999;40:631-6.

Santhosh NS, Sinha S, Satishchandra P. Epilepsy: Indian perspective. Annals of Indian Academy of Neurology. 2014;17(1):S3-11.

Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: A systematic review. PLoS Med. 2007;4(9):e283.

Phatak MA, Hotwani HJ, Deshmukh RK, Panchal SS, Naik SM.Cost analysis of long established and newer oral antiepileptic drugs available in the Indian market. Int J Med Res Health Sci. 2015;4(4):744-48.

Wagle L, Swammy MK, Kempegowda MB. Cost variation Study of antiepileptic drugs available in India. Asian J Pharm Clin Res. 2016;9(2):64-8.

Jana S, Mondal P. Pharmacoeconomics: The need to sensitize undergraduate medical students. Indian J Pharmacol. 2005;37(5):277-8.

Allisabanavar SA, Reddy NS. Cost variation analysis of various brands of anti-epileptic drugs currently available in Indian pharmaceutical market. Int J Basic Clin Pharmacol. 2017;6:1666-9.

Shukla AK, Mehani R. Cost analysis of antiepileptic drugs available in India. Int J Basic Clin Pharmacol. 2016;5:1636-40.

Sai NP, Vedavathi H. Cost analysis study of price variation among the various brands of antiepileptics available in India. Int J Basic Clin Pharmacol. 2017;6:422-6.

Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular outcomes. Circulation. 2009;119:3028-35.

Akila L, Rani RJ. Cost analysis of different brands of antianginal drugs available in India. Int J Basic Clin Pharmacol. 2015;4:860-3.

Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among medicare beneficiaries. Health Affairs. 2003;22(4):220-9.

Gupta RK, Reddy PS. A calm look on cost analysis of different brands of anti-epileptic drugs. JMGIMS. 2011;169(1):64-6.

Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: A literature review. Pharmacy and Therapeutics. 2012;37(1):45-55.

World Health Organisation. Essential drugs and medicines: Drug finance. Available at: Accessed on 20th April, 2021.

Rataboli PV, Garg A. Confusing brand names: nightmare of medical profession. J Postgrad Med. 2005;51:13-6.